drugset / Trial / NCT02670317
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, single arm, phase II trial in young patients (18-60 years) with poor-prognosis (aaIPI 2 or 3) newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Aim of the study is to assess the efficacy and the safety of G-CHOP in combination with ibrutinib.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-02
- Completion
- 2017-02
Outcome
Outcome not reported
Stopped: “GA101-CHOP not advantage from rituximab-CHOP”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Ibrutinib | Small molecule | — | — |
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Vincristine | Small molecule | — | — |